"We are excited to collaborate with Tissue Regeneration Therapeutics to bring their cord-derived cell technologies to the broader Regenerative Medicine market." - Margot Connor, RoosterBio's Chief Executive Officer
FREDERICK, Md. (PRWEB) May 29, 2019
RoosterBio Inc. and Tissue Regeneration Therapeutics Inc.(TRT) today announced a strategic collaboration to advance their shared goal of accelerating the development of the Regenerative Medicine field. This collaboration will productize TRT’s core technology around human umbilical cord-derived mesenchymal stem/stromal cells (hUC-MSCs) to the entire Regenerative Medicine marketplace. This powerful set of biological tools will be made commercially available via integration into RoosterBio’s unique product formats for rapid incorporation into tomorrow’s Regenerative Medicine products.
Within the terms of the agreement, RoosterBio obtains an exclusive worldwide license to TRT’s patent estate related to the manufacture and global sale of human umbilical cord-derived MSCs. RoosterBio will apply their scale up manufacturing expertise, novel human mesenchymal stromal/stem cell (hMSC) product format configurations, and strong commercial engine to drive the comprehensive productization of TRT’s unique and broadly patented technology. TRT’s patent estate includes eight issued patents and several patent applications pending that cover the composition of matter, method of manufacturing, and method of use related to hUC-MSCs. As part of the collaboration, TRT also gains access to RoosterBio’s manufacturing technology platform, supply chain, and bioprocess media at significant discounts to advance process development and clinical translation of their own therapeutic programs. Specific financial terms of the deal were not disclosed.
“We are excited to collaborate with Tissue Regeneration Therapeutics to bring their cord-derived cell technologies to the broader Regenerative Medicine market,” said Margot Connor, RoosterBio’s CEO. She adds, “The products that we launch from this initiative will complement our current hMSC product portfolio, that includes bone marrow-derived and adipose-derived cellular technology, enabling us to reach more customers around the globe. This agreement will significantly benefit both of our companies.”
John E. Davies, DSc, CEO of TRT states “RoosterBio has established itself as a leader in the commercialization of hMSC manufacturing systems, and we are excited to open the availability of our innovative cord cell technology into therapeutic indications that TRT is not pursuing. We believe that the umbilical cord perivascular cell technology has unique advantages over other starting cell types, and we anticipate rapid uptake of these cells in the marketplace. Collaborating with RoosterBio and leveraging their manufacturing expertise and scalable platforms will also accelerate our own therapeutic programs. Overall, this is an impactful collaboration with far reaching implications in the field of Regenerative Medicine.”
Davies and RoosterBio’s Chief Product Officer Jon A. Rowley, PhD will speak at the International Society for Cell & Gene Therapy (ISCT) 2019 Annual Meeting’s MSC Preconference Workshop during a session titled “Next Generation MSC Technologies” on May 29, 2019. To learn more about the new products, visit RoosterBio at ISCT 2019 in Melbourne, Australia at booth number two through June 1, 2019.
The products will be available late summer 2019. To preorder or learn more information about how this technology can radically simplify the use of MSCs, reach us at firstname.lastname@example.org or contact your local RoosterBio sales representative.
About RoosterBio, Inc.
RoosterBio Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.
About Tissue Regeneration Therapeutics Inc.
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) technology platforms that include culture expanded cells (TXP) and engineered cells (eTXP). The latter are designed for specific unmet needs, in addition to the constitutive advantages of TXP, by the engineered secretion of cytokines, growth factors or monoclonal antibodies for targeted therapies. TRT is the first company in the world to have issued and allowed patents in the USA, Europe and Australasia, for extraction of these unique cells from umbilical cord perivascular tissue, and their gene engineering. Additional information is available at http://www.verypowerfulbiology.com.